Tag: Featured Story

Before a single witness testifies at the DEA’s June 29 marijuana rescheduling hearing, the most consequential decision may already be made: who gets into the room. Finalizing the approved participant roster on June 22 is the first real indicator of whether the federal government intends to face the multi-billion-dollar commercial reality of the market — or bury it in administrative bureaucracy.

Trulieve will begin trading on the NYSE after executing a strategic corporate restructuring to maintain a 100-percent medical consolidated footprint.

In a dramatic political paradox, Louisiana lawmakers recently passed a near-unanimous medical cannabis expansion while simultaneously introducing harsh new felony penalties for public consumption. The landmark legislation positions the state as only the second in the nation to mandate medical cannabis access inside hospital walls for terminally ill patients. But behind the bipartisan victory lies a complex web of strict operational boundaries, liability protection, and a sweeping federal opt-out clause that operators must understand.

Aging inventory turns premium flower into discounted cash, making freshness a vital financial control for retailers. When package dates age and velocity slows, dispensary profit margins take a direct hit. But proactive operators do not wait for quality to fade. By adopting proven inventory strategies from the grocery aisle — like FEFO rotation and preventive promotions — dispensaries can protect cash flow, minimize shrink, and stop stale flower from killing their bottom line.

High revenue might catch a buyer’s eye, but it takes more than just strong numbers to close a deal. As federal reclassification reshapes the cannabis industry, acquirers are looking beyond EBITDA to determine a business's true worth. Here are the hidden operational drivers that maximize a dispensary’s valuation and help build a highly scalable, premium acquisition target.

Expanding your cannabis operation is an exciting milestone, but it’s also the exact moment your bank starts paying closer attention. Every new license, state, or investor changes your company's risk profile in the eyes of financial institutions. If left unmanaged, this newfound complexity can unexpectedly put your banking relationships in jeopardy. Two bankers reveal the hidden risks of rapid expansion, why your bank suddenly has so many questions, and how to successfully scale your business without losing access to crucial financial services.

The “wild west” era of craft-scale cannabis edibles is hitting a multi-billion-dollar wall. As global edibles sales head toward a projected $55 billion over the next decade, market survival relies on operational discipline over flashy packaging. Gummy manufacturing remains incredibly volatile, where slight deviations in climate or timing ruin entire batches. To safely scale, the industry must shift from an artisanal test-kitchen mindset to engineered, standardized foundational formulations.

The historic federal shift reclassifying medical marijuana to Schedule III brings undeniable progress, offering long-awaited tax relief from Section 280E. Yet, despite the initial market excitement, rescheduling is not a cure-all for the industry’s deep-rooted liquidity crisis. Cash buyers remain scarce, transactions rely heavily on seller financing, and regulatory fragmentation persists. True competitive advantage in a mature market won’t come from waiting on Washington. It will come from corporate architecture. Here’s why some cannabis operators are looking past policy hype and leveraging independent buyouts to achieve the ultimate business goal: a tax-free exit.

The same United States House of Representatives that voted to let Veterans Administration doctors help vets access medical cannabis also voted, nearly simultaneously, to block the federal rescheduling process that would make such access legally coherent. That is not mixed signals; it is a fractured federal posture. For the roughly 9 million veterans enrolled in VA healthcare, it lands with consequences that are anything but abstract.

Federal efforts to reschedule cannabis typically are framed as a matter of drug policy, centering on taxation, criminal enforcement, and the plant’s classification under the Controlled Substances Act. Yet, this traditional framing increasingly obscures a deeper regulatory transformation. As a partial shift to Schedule III lowers long-standing barriers to genetic research, cannabis is rapidly entering the agricultural biotechnology era. This scientific leap is setting up an unprecedented collision with an unsettled federal oversight landscape. Regulators must now confront whether advanced cannabis innovations will be governed solely as controlled substances or treated as genetically modified crops subject to complex agricultural pest risk oversight.